ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. - Wikidata - awgldk - TriplyDB

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

http://www.wikidata.org/entity/Q36694670

about

H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B An extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancer Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation.High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Protein signature for non-small cell lung cancer prognosis.A network-based biomarker approach for molecular investigation and diagnosis of lung cancer.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination.Selective activation of p53-mediated tumour suppression in high-grade tumours.Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C.Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma.Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking.Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases Differentially expressed and activated proteins associated with non small cell lung cancer tissues High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.Targeting the mitogen-activated protein kinase cascade to treat cancer.Atomic force microscopy characterization of kinase-mediated phosphorylation of a peptide monolayer.Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice.Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC).Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer.A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.Targeting EP4 downstream c-Jun through ERK1/2-mediated reduction of DNMT1 reveals novel mechanism of solamargine-inhibited growth of lung cancer cells ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing.C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

P2860

Q24671049-96096C38-FAE7-4A3F-B611-E8F156C32DC0 Q28484612-20B753F9-AF1C-42EB-96B3-9F304C2DE5EF Q28543407-ECAFDEBC-5442-4004-80B5-E85874F4FB57 Q28596032-5454EFD1-79E9-4F88-9EAA-D3603E5B8E5D Q33671646-87A4C0B8-7444-4F6C-8AF9-909B3BE6FEFC Q33684263-3D9C2940-4466-4666-84CE-2A53BFFD3406 Q33717222-1DC2C2B6-24DC-4EE9-82BF-8BBF933A2092 Q33785608-7943B315-8006-4E26-AC2F-E9715CE66316 Q33787452-B5438A6E-AE8C-4724-B65F-29AE502BFEE8 Q33995206-2317C656-651F-49DE-825B-9D1324AFD7C3 Q34094986-C7F6626C-6CD8-4951-A160-A9A91D47C0B5 Q34151826-DF9BCA10-C53C-44A5-B0D8-E6FB1EE8D17E Q34648711-87647B80-2288-42C1-AE85-32DBFC3624B7 Q34881610-C3CEF199-D6BD-4764-ACAB-EFD09F7F47B1 Q35104755-DF6D158A-454A-4050-9DFF-A406BE95EAFF Q35113376-52D08E67-7592-446C-A751-34C96BF8778C Q35207808-316437C7-B234-4105-8C16-73679D0DD35A Q35207885-8268A881-BF6C-4920-BC28-C610B11CA281 Q35221788-EA2B2AEA-676B-41DD-B83C-4495363F0739 Q35649378-07FE18C4-49AB-4C21-880E-CA92C5C79552 Q35676869-FD01D647-270D-4DE8-B826-3EFA5D1E2D00 Q35805319-22BC57F8-47D3-49E9-AFC4-574AEC4CC2CC Q35805551-3CE777AD-E64B-4B43-93C0-F243242DA244 Q35873526-CB4DDEFA-31CC-438B-B828-438F02693918 Q35968411-CB813256-A9C8-4006-BD89-ADAE1669CDC4 Q36191446-C35F2C2E-588D-4F46-B283-89F35AB3298A Q36511724-54EA7384-B68B-4114-B451-C7858EE11350 Q36528118-7771557A-8568-4593-8B2B-228B144F4CCD Q36640209-374731AF-7121-4DC0-AC75-3A3F31C7E39B Q36643420-1004036A-BEB9-4002-8F83-ED871C338EBB Q36657702-4909AB43-DC9D-4C92-AE70-CCB39C0B47A2 Q36962542-B6C2CEBC-96D7-4642-A2C8-E0B8BE31A5E0 Q37023660-7A5B37B1-0E25-4936-8ED3-F5E1A5136B81 Q37406949-16051A4D-BA9F-4CE7-836D-01FF0B57F512 Q37573669-C486954F-6461-4AEA-9CF6-0A41A26448B2 Q37604381-D7E01E79-BFFD-4822-BAF3-981FD3915C3E Q37656142-B4A1B234-2BEB-4B6A-A7ED-34CF47D1EE42 Q37667783-F2B14CFF-55A1-439F-B3ED-6CF009EBAC9D Q38583728-DCB65F5B-CD68-4818-A7FB-E04B1D65F8E0 Q38854172-55A467C9-02CD-449C-B5C5-685CA2B38D40

P2860

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

http://www.wikidata.org/entity/Q36694670

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@ast

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@en

type

label

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@ast

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@en

prefLabel

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@ast

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

@en

P1433

Q36694670-77691434-0397-4633-844D-E9D8717B1F93

P1476

Q36694670-FB8A9A44-A202-4FFA-AD86-237F118BF173

P2093

Q36694670-10D54E3A-009D-4289-B097-687AB2F94B77

Q36694670-12117E54-D209-445B-998C-050FDC7DE243

Q36694670-151502F4-32B9-4512-8D88-8BEEAD94294C

Q36694670-60B4966C-0739-490D-A33A-9E1FDE2051BD

Q36694670-61D88BCE-D058-4548-BC7E-3AF61852B4AF

Q36694670-9E61EB0F-7C21-4EBC-9C62-9EF8F48EBF6B

Q36694670-BD68A4A0-634D-4B10-BCAF-50D084CB638E

Q36694670-DD23058F-880C-40CF-8DFC-D3B025A49E81

Q36694670-F9778F75-C357-4A05-ABF0-5453B1D7B03E

P2860

Q36694670-011AB023-019E-4EB5-83BE-56E08DCD1FF4

Q36694670-14F8922B-2CBB-4FE9-A3E0-37AC1E6AC47C

Q36694670-1F96F871-5FD0-473E-85FA-4A0CB38A0609

Q36694670-23790CED-8700-4040-8ABB-44E42CD03E4E

Q36694670-257B4A8F-426A-4791-B98F-5F4D7B011980

Q36694670-295E2591-F009-422D-A17F-855B7576827A

Q36694670-400F8031-4A0A-432B-9D4B-004BC0C80A1E

Q36694670-433F2CD2-D2E5-4ED8-B2DC-14B2F15A6FEC

Q36694670-4465B303-9AD7-4AEC-BE48-29AEF4B11C17

Q36694670-627AC8AC-0129-4929-AE10-3EE1C728C6B7

P2888

Q36694670-CB46B699-9666-4FF5-AA7C-9BF04FA66E24

P304

Q36694670-C68DA6C0-ECC1-4A7E-898E-6DF9C60A00FF

P31

Q36694670-60E04776-EA49-403D-8CB2-4913444F2AFA

P356

Q36694670-68E3DE0E-FA00-47D8-AB4A-F96029B64628

P407

Q36694670-DC306DCC-8459-4029-9B48-554B2AA0C1C3

P433

Q36694670-3DFB0758-72C4-402A-9B0D-B61B66E31F14

P478

Q36694670-FD8CF216-073E-4BDF-AD2C-B37E2546CEC1

P50

Q36694670-019D0E06-A01B-4E98-81EF-6048B607DAB1

Q36694670-5FFD99FB-7FC6-45D1-A3CF-CFC66071978F

P577

Q36694670-B994BD01-5119-47D2-8D2D-247CF04385CB

P5875

Q36694670-E4B4BCA5-2CEF-4481-AC79-A6A0E840972F

P698

Q36694670-773D6CA3-23C3-44F7-984B-0F04DC6A0E02

P932

Q36694670-F6F168DD-8ECE-462A-8AB5-CD94760FA435

P356

P1433

British Journal of Cancer

P1476

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

@en

P2093

C Garcia-Corchón

http://www.w3.org/2001/XMLSchema#string

C Quero

http://www.w3.org/2001/XMLSchema#string

G Toledo

http://www.w3.org/2001/XMLSchema#string

J-C Soria

http://www.w3.org/2001/XMLSchema#string

L M Montuenga

http://www.w3.org/2001/XMLSchema#string

M D Lozano

http://www.w3.org/2001/XMLSchema#string

R G Manzano

http://www.w3.org/2001/XMLSchema#string

S Martín-Algarra

http://www.w3.org/2001/XMLSchema#string

W Torre

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian MAP kinase signalling cascades

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

A synthetic inhibitor of the mitogen-activated protein kinase cascade

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human

In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms.

Activation of mitogen-activated protein kinase associated with prostate cancer progression.

MAP kinase pathways.

P2888

P304

1047-1052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601644

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Silvestre Vicent

José María López-Picazo

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8680462

http://www.w3.org/2001/XMLSchema#string

P698

14997206

http://www.w3.org/2001/XMLSchema#string

P932

2409626

http://www.w3.org/2001/XMLSchema#string